About ipsen sa - IPSEF
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. It operates through the following segments: Specialty Care. The Specialty Care segment focuses on oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and rare diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.
IPSEF At a Glance
Ipsen SA
65, quai Georges Gorse
Boulogne-Billancourt, Ile-de-France 92650
| Phone | 33-1-58-33-50-00 | Revenue | 3.68B | |
| Industry | Pharmaceuticals: Major | Net Income | 374.16M | |
| Sector | Health Technology | 2024 Sales Growth | 8.79% | |
| Fiscal Year-end | 12 / 2025 | Employees | 5,358 | |
| View SEC Filings |
IPSEF Valuation
| P/E Current | 22.899 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 25.356 |
| Price to Sales Ratio | 2.599 |
| Price to Book Ratio | 2.19 |
| Price to Cash Flow Ratio | 9.74 |
| Enterprise Value to EBITDA | 8.378 |
| Enterprise Value to Sales | 2.553 |
| Total Debt to Enterprise Value | 0.057 |
IPSEF Efficiency
| Revenue/Employee | 686,524.372 |
| Income Per Employee | 69,831.436 |
| Receivables Turnover | 4.062 |
| Total Asset Turnover | 0.539 |
IPSEF Liquidity
| Current Ratio | 1.343 |
| Quick Ratio | 1.153 |
| Cash Ratio | 0.45 |
IPSEF Profitability
| Gross Margin | 73.766 |
| Operating Margin | 19.67 |
| Pretax Margin | 12.695 |
| Net Margin | 10.172 |
| Return on Assets | 5.64 |
| Return on Equity | 9.00 |
| Return on Total Capital | 7.915 |
| Return on Invested Capital | 8.244 |
IPSEF Capital Structure
| Total Debt to Total Equity | 12.333 |
| Total Debt to Total Capital | 10.979 |
| Total Debt to Total Assets | 8.009 |
| Long-Term Debt to Equity | 9.394 |
| Long-Term Debt to Total Capital | 8.362 |